Duke University and Affymetrix Initiate Five-Year Translational Research Collaboration

Duke researchers will use Affymetrix' GeneChip HT(High-Throughput) System and arrays to perform large-scale clinicalstudies. The Affymetrix technology will enable them to more rapidlydiscover RNA and DNA patterns that can better classify, manage andtreat complex diseases. As part of the agreement, Affymetrix will fundcreative research and clinical projects that could lead to new genomicapplications on the GeneChip platform, as well as novel diagnosticsand screening tests.

"This is an exciting time when genomics offers the promise of adeeper understanding of biology while at the same time improving thepractice of medicine," said Joseph Nevins, Ph.D., director of the IGSPCenter for Applied Genomics & Technology at Duke University. "Bycombining our research expertise with Affymetrix' high-throughputmicroarray technology, we have the opportunity to build on our priorwork and develop gene expression profiles that characterize oncogenicpathways and define tumor phenotypes, which are important indetermining clinical outcomes. At the same time, this can translateinto improved clinical care and provide an important resource toenhance the use of microarray technology for all Duke investigators."

"Affymetrix is excited to be working with a leading researchorganization such as Duke University to help bring more effectivepersonalized tests and therapies to market faster," said Gregg Fergus,senior vice president, Global Sales Operations at Affymetrix."Together, we hope to accelerate clinical research, improve patientcare and open the door to new genomic applications."

Affymetrix collaborates with academic institutions and patientadvocacy groups through the company's translational medicine programto develop more effective treatments. Affymetrix GeneChip microarraytechnology helps researchers tailor treatments for individual patientsby identifying and measuring the genetic information associated withcomplex diseases. The translational medicine program complements thePowered by Affymetrix(TM) program, which enables companies to licenseGeneChip technology to develop innovative microarray products. Thiscustom-designed technology is being used in many applications,including diagnostics, forensics, animal, industrial and food testing.

About Affymetrix

Affymetrix scientists invented the world's first high-densitymicroarray in 1989 and began selling the first commercial microarrayin 1994. Since then, Affymetrix GeneChip(R) technology has become theindustry standard in molecular biology research. Affymetrix technologyis used by the world's top pharmaceutical, diagnostic andbiotechnology companies as well as leading academic, government andnot-for-profit research institutes. More than 1,300 systems have beeninstalled around the world and nearly 3,000 peer-reviewed papers havebeen published using the technology. Affymetrix' patentedphotolithographic manufacturing process provides the most informationcapacity available today on an array, enabling researchers to use awhole-genome approach to analyzing the relationship between geneticsand health. Affymetrix is headquartered in Santa Clara, Calif., withmanufacturing facilities in Sacramento, Calif., and Bedford, Mass. Thecompany maintains important sales and marketing operations in Europeand Asia and has about 1,000 employees worldwide. For more informationabout Affymetrix, please visit the company's Web site atwww.affymetrix.com.

All statements in this press release that are not historical are"forward-looking statements" within the meaning of Section 21E of theSecurities Exchange Act as amended, including statements regardingAffymetrix' "expectations," "beliefs," "hopes," "intentions,""strategies," or the like. Such statements are subject to risks anduncertainties that could cause actual results to differ materially forAffymetrix from those projected, including, but not limited to: risksof the Company's ability to achieve and sustain higher levels ofrevenue, higher gross margins, reduced operating expenses;uncertainties relating to technological approaches, manufacturing(including risks related to the Company's ability to achieve hoped-formanufacturing yields for certain array products, including the abilityto identify and resolve manufacturing problems), product development(including uncertainties relating to commercial and technologicalsuccess of the strategic alliance between Duke University andAffymetrix discussed in this press release); personnel retention;uncertainties related to cost and pricing of Affymetrix products;dependence on collaborative partners; uncertainties relating to solesource suppliers; uncertainties relating to FDA and other regulatoryapprovals; competition; risks relating to intellectual property ofothers and the uncertainties of patent protection and litigation.These and other risk factors are discussed in Affymetrix' Form 10-Kfor the year ended December 31, 2004, and other SEC reports, includingits Quarterly Reports on Form 10-Q for subsequent quarterly periods.Affymetrix expressly disclaims any obligation or undertaking torelease publicly any updates or revisions to any forward-lookingstatements contained herein to reflect any change in Affymetrix'expectations with regard thereto or any change in events, conditionsor circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip are registeredtrademarks owned or used by Affymetrix Inc.